Wound treatment biotech to launch on NASDAQ

Israel’s Macrocure’s white blood cell injections treat hard-to-heal and chronic wounds. It wants to raise $75 million from an IPO on NASDAQ to finance its CureXcell a cell-based therapy that restores the natural balance required for the wound healing process.

This entry was posted in Economy & Business. Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *